First PREMIER Bank’s SAB Biotherapeutics SABS Stock Holding History

First PREMIER Bank’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74K	Hold	18,986	–	–	0.01%	219
2026 Q1	$73K	Hold	18,986	–	–	0.02%	210
2025 Q4	$71K	Hold	18,986	–	–	0.02%	208
2025 Q3	$38K	Hold	18,986	–	–	0.01%	248
2025 Q2	$33K	Hold	18,986	–	–	0.01%	249
2025 Q1	$26K	Hold	18,986	–	–	0.01%	260
2024 Q4	$72K	Sell	18,986 -400	-2%	-$1.31K	0.02%	208
2024 Q3	$52K	Hold	19,386	–	–	0.01%	231
2024 Q2	$60K	Buy	+19,386	New	+$71.1K	0.02%	201
2024 Q1	–	Sell	-80,754	Closed	-$555K	–	509
2023 Q4	$555K	Hold	80,754	–	–	0.16%	101
2023 Q3	$509K	Hold	80,754	–	–	0.16%	100
2023 Q2	$670K	Hold	80,754	–	–	0.19%	90
2023 Q1	$355K	Hold	80,754	–	–	0.1%	116
2022 Q4	$476K	Hold	80,754	–	–	0.14%	95
2022 Q3	$566K	Buy	80,754 +15,510	+24%	+$154K	0.18%	90
2022 Q2	$946K	Buy	+65,244	New	+$1.37M	0.28%	76
2022 Q1	–	Sell	-83,256	Closed	-$6.5M	–	383
2021 Q4	$6.5M	Buy	+83,256	New	+$7.81M	1.68%	16

Other funds holding SABS

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

First PREMIER Bank's SABS Position: Q2 2026 in Review

First PREMIER Bank held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 18,986 shares worth $74K. The position accounts for 0.01% of the portfolio, ranked #219.

First PREMIER Bank first reported a position in SABS in Q4 2021 and has held it in 17 quarters since. The position peaked at $6.5M in Q4 2021. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

First PREMIER Bank held 18,986 shares of SAB Biotherapeutics worth $74K as of Q2 2026.
First PREMIER Bank left its SAB Biotherapeutics share count unchanged in Q2 2026.
SAB Biotherapeutics made up 0.01% of First PREMIER Bank's portfolio in Q2 2026, its #219 holding.
First PREMIER Bank first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 17 quarters since.
First PREMIER Bank's SAB Biotherapeutics position peaked at $6.5M in Q4 2021.
87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on First PREMIER Bank's 13F filing for Q2 2026, filed 15 Jul 2026.